We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+15.2%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$101M
AUM Growth
+$4.03M
Cap. Flow
-$1.4M
Cap. Flow %
-1.38%
Top 10 Hldgs %
69.32%
Holding
57
New
10
Increased
16
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$7.65M
2
ARVN icon
Arvinas
ARVN
+$3.68M
3
CDTX
Cidara Therapeutics
CDTX
+$2.4M
4
STRO icon
Sutro Biopharma
STRO
+$1.66M
5
TARA icon
Protara Therapeutics
TARA
+$1.63M

Top Sells

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$8.32M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.19M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$1.36M
4
TIL icon
Instil Bio
TIL
+$1.2M
5
IMNM icon
Immunome
IMNM
+$1.03M

Sector Composition

Rank Sector Weight
1 Healthcare 98.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TENX icon
26
Tenax Therapeutics
TENX
$64.4M
$480K 0.47%
83,333
– –
CRBP icon
27
Corbus Pharmaceuticals
CRBP
$189M
$407K 0.4%
59,000
– –
KPRX icon
28
Kiora Pharmaceuticals
KPRX
$11.7M
$352K 0.35%
122,223
– –
PTGX icon
29
Protagonist Therapeutics
PTGX
$9.84B
$204K 0.2%
+3,700
New +$178K
CTMX icon
30
CytomX Therapeutics
CTMX
$760M
$170K 0.17%
75,000
– –
NRIX icon
31
Nurix Therapeutics
NRIX
$2.76B
$114K 0.11%
+10,000
New +$108K
GERN icon
32
Geron
GERN
$1.01B
$98.7K 0.1%
70,000
-585,000
-89% -$829K
WVE icon
33
Wave Life Sciences
WVE
$1.03B
$97.5K 0.1%
15,000
+2,000
+15% +$13.2K
LRMR icon
34
Larimar Therapeutics
LRMR
$454M
$95.4K 0.09%
33,000
+5,000
+18% +$11.6K
GOSS icon
35
Gossamer Bio
GOSS
$86.8M
$92.3K 0.09%
75,000
– –
PRQR icon
36
ProQR Therapeutics
PRQR
$262M
$91.8K 0.09%
45,000
– –
VTYX
37
DELISTED
Ventyx Biosciences
VTYX
$85.6K 0.08%
40,000
– –
ERAS icon
38
Erasca
ERAS
$6.45B
$82.5K 0.08%
65,000
+15,000
+30% +$20.1K
ALEC icon
39
Alector
ALEC
$240M
$77K 0.08%
55,000
– –
TERN
40
DELISTED
Terns Pharmaceuticals
TERN
$74.6K 0.07%
20,000
+3,000
+18% +$9.37K
DSGN icon
41
Design Therapeutics
DSGN
$917M
$67.4K 0.07%
20,000
+6,000
+43% +$22.5K
CNTX icon
42
Context Therapeutics
CNTX
$43.2M
$65.5K 0.06%
100,000
+10,000
+11% +$7.19K
OVID icon
43
Ovid Therapeutics
OVID
$489M
$52.8K 0.05%
160,000
+63,000
+65% +$19K
IMMX icon
44
Immix Biopharma
IMMX
$809M
$51.8K 0.05%
+25,000
New +$50.3K
YARW
45
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$49.5K 0.05%
+600
New +$39K
ACRS icon
46
Aclaris Therapeutics
ACRS
$860M
$46.4K 0.05%
32,700
-2,300
-7% -$3.11K
FDMT icon
47
4D Molecular Therapeutics
FDMT
$621M
$44.5K 0.04%
12,000
– –
PYXS icon
48
Pyxis Oncology
PYXS
$201M
$44K 0.04%
+40,000
New +$45.1K
PMVP icon
49
PMV Pharmaceuticals
PMVP
$67.2M
$37.1K 0.04%
35,000
– –
NXTC icon
50
NextCure
NXTC
$37.4M
$20.7K 0.02%
3,750
+1,667
+80% +$8.95K
1
2
3

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
RP
RIHO Partners Tucson, Arizona $159M AUM
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return
RCWM
Royal Capital Wealth Management Carmel, Indiana $161M AUM 18.42% 1-Year Est. Return

Velan Capital Investment Management's Q2 2025 Portfolio in Review

As of Q2 2025, Velan Capital Investment Management held 57 positions worth $101M, up 4.1% from $97.2M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Velan Capital Investment Management's Q2 2025 filing shows 10 new, 16 increased, 5 reduced and 7 closed positions. Its largest new stake was Alumis Inc: 1,620,846 shares worth $4.86M. The largest sale was ACELYRIN, an estimated $8.32M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Velan Capital Investment Management's largest Q2 2025 buy was Alumis Inc: 1,620,846 shares worth $4.86M.
  • Velan Capital Investment Management added most to Sutro Biopharma in Q2 2025, an estimated $1.66M increase.
  • Velan Capital Investment Management's biggest Q2 2025 reduction was Praxis Precision Medicines, cutting an estimated $1.36M.
  • Velan Capital Investment Management fully exited ACELYRIN in Q2 2025, selling an estimated $8.32M.
  • Velan Capital Investment Management's ten largest holdings make up 69% of its $101M portfolio in Q2 2025.
  • Velan Capital Investment Management opened 10 new positions and closed 7 in Q2 2025.
  • Velan Capital Investment Management's portfolio value rose 4.1% quarter-over-quarter to $101M.

Based on Velan Capital Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.